Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘LODR Regulations’) and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, Emcure Pharmaceuticals has informed that Marcan Pharmaceuticals Inc., a subsidiary of the Company (‘Marcan’) has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (‘Mantra’), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: